Published in Cancer Weekly, June 17th, 2003
"Childhood B-cell neoplasms account for approximately 2%" of pediatric ALL cases, scientists in Switzerland explained. "The short but intensive chemotherapy yields a currently 75% to 85% event-free survival."
However, "the prognosis for children with relapsed disease is considered to be dismal," according to S. Corbacioglu and coauthors at the University of Zurich, who described their experience with "a 12-year old boy diagnosed with B-cell ALL with central nervous system (CNS)...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.